CN101812059A - Nitric oxide donor-type farnesyl thiosalicylic acid derivative, and preparation method and medical application thereof - Google Patents

Nitric oxide donor-type farnesyl thiosalicylic acid derivative, and preparation method and medical application thereof Download PDF

Info

Publication number
CN101812059A
CN101812059A CN 201010146029 CN201010146029A CN101812059A CN 101812059 A CN101812059 A CN 101812059A CN 201010146029 CN201010146029 CN 201010146029 CN 201010146029 A CN201010146029 A CN 201010146029A CN 101812059 A CN101812059 A CN 101812059A
Authority
CN
China
Prior art keywords
oxygen
fta
preparation
type
oxadiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 201010146029
Other languages
Chinese (zh)
Other versions
CN101812059B (en
Inventor
张奕华
凌勇
赖宜生
叶小磊
季晖
彭司勋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN2010101460292A priority Critical patent/CN101812059B/en
Publication of CN101812059A publication Critical patent/CN101812059A/en
Application granted granted Critical
Publication of CN101812059B publication Critical patent/CN101812059B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Abstract

The invention discloses a nitric oxide (NO) donor-type farnesyl thiosalicylic acid (FTA) derivative, and pharmaceutically acceptable salt, a preparation method and medical application thereof. The FTA derivative is a compound obtained by carrying out heterozygosis on a NO donor furazan nitrogen oxide and Ras protein inhibitor FTA by an ester bond or an amido bond. Pharmacological test results show that the FTA derivative can reserve the Ras protein inhibiting activity of FTA and simultaneously releases high-concertration NO to induce cancer cell apoptosis and enhance the inhibiting action on cancer cell proliferation; compared with the FTA, the FTA derivative has more excellent anti-tumor activity, and therefore, the compound can be suitable for treating various clinical malignant tumours.

Description

Nitric oxide donator type farnesyl thio-salicylic acid derivative, its preparation method and medicinal use thereof
Technical field
The present invention relates to pharmaceutical field, be specifically related to a class nitric oxide donator type farnesyl thio-salicylic acid derivative and a pharmacy acceptable salt thereof, their preparation method, contain the medicinal compositions of these derivatives and their medicinal use, particularly the application in the preparation antitumor drug.
Background technology
Alltrans farnesyl thiosalicylic acid (is called for short: FTA, trade(brand)name: Salirasib) as new Ras protein inhibitor based on farnesyl transferase, can competitive replace F-Ras and the F-Ras mutain combines with Galectins, inhibition causes downstream signal path (comprising Raf and P13K signal path) and mTOR (tumorigenic stimulator by Ras, it can rely on or open the P13K signal path independently), thus the growth of tumour cell suppressed.Studies show that FTA can suppress kinds of tumors (cerebral glioma, liver cancer, lung cancer, carcinoma of the pancreas, mammary cancer, colorectal carcinoma etc.) cell proliferation and migration (Haklai, R.; Elad-Sfadia, G.; Egozi, Y.et al.Cancer Chemother Pharmacol, 2008,61 (1): 89-96; Tsimberidou, A.M.; Rudek, M.A.; Hong, D.et al.Cancer Chemother Pharmacol, 2009,65 (2): 235-241; Zundelevich, A.; Elad-Sfadia, G.; Haklai, R.et al.Mol Cancer Ther, 2007,6 (6): 1765-1773).FTA treats the II phase clinical study well afoot of lung cancer and carcinoma of the pancreas at present.
Figure GSA00000083319200011
The farnesyl thiosalicylic acid (FTA, Salirasib)
Nitrogen protoxide (NO) is important courier's material and an effector molecule in the mammalian body.In recent years, the NO effect in generation, development and the death of tumour having become one of focus of tumor research and treatment (Mocellin S.Curr Cancer DrugTargets, 2009,9 (2): 214-236; Coulter JA, McCarthy HO, Xiang J, et al.Nitric Oxide, 2008,19 (2): 192-198).Studies show that in a large number the NO that continues lower concentration in the body can promote the growth of cell to suppress apoptosis; The NO of high density then produces cytotoxicity, inducing apoptosis of tumour cell, the diffusion and transfer (Huerta S, Chilka S, Bonavida B.Int J Oncol, 2008,33 (5): 909-927) that stop tumour cell.
The NO donor is meant that a class discharges the compound of a certain amount of NO in vivo through enzyme or non-enzyme effect.Furazan oxynitride (Furoxan) is the important NO donor of a class, has anti-tumor activity (Chen L, Zhang Y, Kong X, et al.J Med Chem, 2008,51 (15): 4834-4838) by the higher concentration NO of its generation.
For obtaining the compound more excellent than FTA anti-tumor activity, we have carried out the structural modification research of FTA.The invention discloses furazan oxynitride class NO donator type FTA derivative and pharmacy acceptable salt thereof that a class has pharmaceutical use, have not yet to see any report this compounds.
Summary of the invention
The present invention discloses furazan oxynitride class NO donator type FTA derivative and pharmacy acceptable salt, its preparation method and the medicinal use thereof that a class has anti-tumor activity first.The pharmacological results shows, the Ras albumen that FTA derivative of the present invention can keep FTA suppresses active, discharge higher concentration NO simultaneously, cell death inducing, enhancing is to the restraining effect of cancer cell multiplication, have better anti-tumor activity than FTA, therefore, this compounds may be applicable to the multiple clinically malignant tumour of treatment.
New compound disclosed by the invention is FTA derivative and the pharmacy acceptable salt thereof shown in general formula I, the II:
Figure GSA00000083319200021
In the general formula I: X representative-O-,-N-or-NH-; R representative-(CH 2) n-, n=2～6 ,-CH (CH 3) CH 2-,-CH (CH 3) (CH 2) 2-,-(CH 2) 2O (CH 2) 2-,-PhCH 2-,-(CH 2CH 2OH) CH 2CH 2-,-(CH 2) 2NH (CH 2) 2-,-(CH 2) 2NBoc (CH 2) 2-,-(CH 3) CH 2CH 2-,-(CH 2CH 2) 2NCH 2CH 2-,-(CH 2CH 2) 2CH (CH 2) n-, n=0～2 ,-(CH 2CH 2CH 2) CHCH 2-,-CH 2CH=CHCH 2-or-CH 2C ≡ CCH 2-;
Among the general formula I I :-NH-A-CO-represents glycine, Beta-alanine, γ-An Jidingsuan, L-or D-type L-Ala, L-or D-type Xie Ansuan, L-or D-type leucine, L-or D-type Isoleucine, L-or D-type methionine(Met), L-or D-type halfcystine, L-or D-type phenylalanine, L-or D-type tyrosine, L-or D-type tryptophane, L-or D-type arginine, L-or D-type proline(Pro), L-or D-type histidine residues; X representative-O-,-N-or-NH-; R representative-(CH 2) n-, n=2～6 ,-CH (CH 3) CH 2-,-CH (CH 3) (CH 2) 2-,-(CH 2) 2O (CH 2) 2-,-PhCH 2-,-(CH 2CH 2OH) CH 2CH 2-,-(CH 2) 2NH (CH 2) 2-,-(CH 2) 2NBoc (CH 2) 2-,-(CH 3) CH 2CH 2-,-(CH 2CH 2) 2NCH 2CH 2-,-(CH 2CH 2) 2CH (CH 2) n-, n=0～2 ,-(CH 2CH 2CH 2) CHCH 2-,-CH 2CH=CHCH 2-or-CH 2C ≡ CCH 2-.
The preferred compound of the present invention is FTA derivative shown in the general formula I and medically acceptable salt thereof: X representative-O-,-N-or-NH-; R representative-(CH 2) n-, n=2～6 ,-CH (CH 3) (CH 2) 2-,-(CH 2) 2O (CH 2) 2-,-(CH 2CH 2OH) CH 2CH 2-,-(CH 2) 2NH (CH 2) 2-,-(CH 2) 2NBoc (CH 2) 2-,-(CH 3) CH 2CH 2-,-(CH 2CH 2) 2CH-,-(CH 2CH 2) 2NCH 2CH 2-,-(CH 2CH 2CH 2) CHCH 2-,-CH 2CH=CHCH 2-or-CH 2C ≡ CCH 2-.
The preferred compound of the present invention is that FTA derivative shown in the general formula I I and medically acceptable salt :-NH-A-CO-thereof represent glycine, Beta-alanine, L-or D-type L-Ala, L-or D-type phenylalanine, L-or D-type proline(Pro), L-or D-type leucine residue; X representative-O-,-N-or-NH-; R representative-(CH 2) n-, n=2～6 ,-CH (CH 3) (CH 2) 2-,-(CH 2) 2O (CH 2) 2-,-CH 2CH=CHCH 2-or-CH 2C ≡ CCH 2-.
The further preferred compound of the present invention is FTA derivative shown in the general formula I and medically acceptable salt thereof: X representative-O-,-N-or-NH-; R representative-(CH 2) n-, n=2～6 ,-CH (CH 3) (CH 2) 2-,-(CH 2) 2O (CH 2) 2-,-(CH 2CH 2OH) CH 2CH 2-,-(CH 2) 2NH (CH 2) 2-,-(CH 2) 2NBoc (CH 2) 2-,-(CH 3) CH 2CH 2-,-(CH 2CH 2) 2NCH 2CH 2-,-(CH 2CH 2) 2CH-,-(CH 2CH 2CH 2) CHCH 2-or-CH 2C ≡ CCH 2-;
The further preferred compound of the present invention is FTA derivative shown in the general formula I I and medically acceptable salt thereof:
-NH-A-CO-represents glycine, Beta-alanine, L-L-Ala, L-phenylalanine, L-proline(Pro) or L-leucine residue; X representative-O-,-N-or-NH-; R representative-(CH 2) n-, n=2～6 ,-CH (CH 3) (CH 2) 2-,-(CH 2) 2O (CH 2) 2-or-CH 2C ≡ CCH 2-.
Concretely, the FTA derivative shown in general formula I, the II is preferably from following compounds:
N-{2-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] ethyl } farnesyl thiosalicylic acid acid amides
(compound number: I 1, down together)
N-{[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group } the inferior acid amides (I of piperazinyl farnesyl thiosalicylic acid 2)
4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)]-the 2-alkynyl } farnesyl thiosalicylic acid butyl ester (I 3)
N-{4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] piperidyl } the inferior acid amides (I of farnesyl thiosalicylic acid 4)
N-{3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] propyl group } farnesyl thiosalicylic acid acid amides (I 5)
N-{N-methyl-2-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] ethyl } the inferior acid amides (I of farnesyl thiosalicylic acid 6)
1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] } farnesyl thiosalicylic acid propyl ester (I 7)
N-{2-{[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] methoxyl group } pyrrolidyl } the inferior acid amides (I of farnesyl thiosalicylic acid 8)
2-{N-tertbutyloxycarbonyl-2-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] ethylamino-} farnesyl thiosalicylic acid ethyl ester (I 9)
2-{[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] ethylamino-} farnesyl thiosalicylic acid ethyl ester (I 10)
N-{N-[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] hydroxyethyl } farnesyl thiosalicylic acid ethanamide (I 11)
N-{ acetate-1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] propyl ester } farnesyl thiosalicylic acid acid amides (II 1)
N-{ acetate-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] butyl ester } farnesyl thiosalicylic acid acid amides (II 2)
N-{ acetate-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)]-2-alkynes-butyl ester } farnesyl thiosalicylic acid acid amides (II 3)
N-{ acetate-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] ethanamide } farnesyl thiosalicylic acid acid amides (II 4)
N-{2-propionic acid-1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] propyl ester } farnesyl thiosalicylic acid acid amides (II 5)
N-{2-propionic acid-2-[[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group] ethyl ester } farnesyl thiosalicylic acid acid amides (II 6)
N-{2-Pyrrolidine formic acid-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] butyl ester } the inferior acid amides (II of farnesyl thiosalicylic acid 7)
N-{2-propionic acid-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] butyl ester } farnesyl thiosalicylic acid acid amides (II 8)
N-{2-propionic acid-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)]-2-alkynes-butyl ester } farnesyl thiosalicylic acid acid amides (II 9)
N-{2-phenylpropionic acid-2-[[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group] ethyl ester } farnesyl thiosalicylic acid acid amides (II 10)
N-{2-Pyrrolidine formic acid-1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] propyl ester } the inferior acid amides (II of farnesyl thiosalicylic acid 11)
N-{2-Pyrrolidine formic acid-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)]-2-alkynes-butyl ester } the inferior acid amides (II of farnesyl thiosalicylic acid 12)
N-{2-Pyrrolidine formic acid-2-[[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group] ethyl ester } the inferior acid amides (II of farnesyl thiosalicylic acid 13)
N-{ acetate-2-[[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group] ethyl ester } farnesyl thiosalicylic acid acid amides (II 14)
N-{N '-[2-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] propyl group]-the 2-propionic acid amide } farnesyl thiosalicylic acid acid amides (II 15)
N-{2-isocaproic acid-1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] propyl ester } farnesyl thiosalicylic acid acid amides (II 16)
N-{ propionic acid-2-[[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group] ethyl ester } farnesyl thiosalicylic acid acid amides (II 17)
Another object of the present invention is to provide the preparation method of general formula I of the present invention, the described compound of II.
FTA derivative shown in the general formula I prepares by following manner: 2-oxygen-3; 4-two benzenesulfonyls-1; 2; the 5-oxadiazole generates furazan oxynitride (1) with hydrocarbon based diol or the reaction of alkyl hydramine under the sodium hydroxide effect; FTA is at N; N '-dicyclohexylcarbodiimide (DCC) and DMAP effect are descended and furazan oxynitride (1) reaction makes compound of Formula I, and its synthetic route is as follows:
Figure GSA00000083319200051
Wherein, X and R's is described as defined above.
Furazan oxynitride (1) reference (Acta Pharmaceutica Sinica, 2001,36 (11): 821-826) preparation.The organic solvent that reaction is adopted is selected from methylene dichloride, chloroform, tetrahydrofuran (THF), ethyl acetate, ethyl formate, methyl acetate, 1, the mixture of 2-ethylene dichloride, benzene, toluene, dioxane, DMF or above-mentioned solvent preferentially adopts anhydrous methylene chloride or anhydrous tetrahydro furan.
FTA derivative shown in the general formula I I prepares by following manner: under DCC and DMAP effect; furazan oxynitride (1) generates intermediate (3) with amino acid (2) reaction of Boc protection; take off Boc through trifluoroacetic acid (TFA) and obtain compound (4); under 1-ethyl-(3-dimethylaminopropyl) carbodiimide (EDC) and DMAP effect; make with the FTA reaction, its synthetic route is as follows:
Wherein, X and R's is described as defined above.
The organic solvent that reaction is adopted is selected from methylene dichloride, chloroform, tetrahydrofuran (THF), ethyl acetate, ethyl formate, methyl acetate, 1, the mixture of 2-ethylene dichloride, benzene, toluene, dioxane, DMF or above-mentioned solvent preferentially adopts anhydrous methylene chloride, anhydrous tetrahydro furan or DMF.
A further object of the present invention provides general formula I of the present invention, the application of II compound in preparation medicine for treating tumor thing.
Further purpose of the present invention is to provide a kind of pharmaceutical composition that contains general formula I of the present invention, II compound and the pharmaceutically acceptable carrier or the auxiliary material of effective dosage.
The compounds of this invention can be made preparation for administration separately or with one or more pharmaceutically acceptable carrier combinations.For example, solvent, thinner etc. can be used the oral dosage form administration, but as tablet, capsule dispersed powders, granule etc.The various formulations of pharmaceutical composition of the present invention can be prepared according to the method for knowing in the pharmaceutical field.Can contain for example activeconstituents of 0.05%～90% weight with carrier combinations in these medicinal preparationss, the activeconstituents of weight between more common about 15%～60%.The compounds of this invention dosage can be 0.005～5000mg/kg/ days, also can exceed this dosage range according to the different using dosages of disease severity or formulation.
The compounds of this invention can with other antitumor drugs for example alkylating agent (as endoxan or cis-platinum), antimetabolite (as 5 FU 5 fluorouracil or hydroxyurea), topoisomerase enzyme inhibitor (as camptothecine), mitotic inhibitor (as taxol or vinealeucoblastine(VLB)), DNA intercalating agent (as Zorubicin) combined utilization, in addition can also with the radiotherapy combined utilization.These other antitumor drugs or radiotherapy can give simultaneously or at different time with The compounds of this invention.Thereby these combination therapys can produce synergy helps to improve result of treatment.
Be the part pharmacological testing and the result of The compounds of this invention below:
The structure of the compound code name correspondence of pharmacological testing part sees Table 1 and table 2.
Table 1 formula I part of compounds code name and corresponding structure thereof
Figure GSA00000083319200072
Figure GSA00000083319200073
Table 2 formula II part of compounds code name and corresponding structure thereof
Figure GSA00000083319200081
1, anti tumor activity in vitro research
1.1 the blue colorimetry antitumor activity in vitro of tetramethyl-nitrogen azoles
Adopt the blue colorimetry of tetramethyl-nitrogen azoles (MTT) to estimate the antiproliferative activity of The compounds of this invention routinely to 13 kinds of human cancer cell strains.Mtt assay has been widely used in the responsive mensuration of large-scale screening anti-tumor medicine, cell toxicity test and tumour radiotherapy etc.Suo Lafeini (Sorafenib) is widely used clinically at present antitumor drug, and its action target is exactly the Ras signal pathway, therefore selects it as positive control drug.
Human cancer cell strain: breast cancer cell MCF-7, MDA-MB-231, liver cancer cell Hep G2, Hep 3B, BEL-7402, kidney cancer cell 786-O, OS-RC-2, lung cell A549, H460, H520, brain cancer cell U251, U87, stomach cancer cell SGC-7901.
Experimental technique is as follows: get and be in one bottle in cell in good condition exponential phase of growth, add 0.25% tryptic digestion, attached cell is come off, make every milliliter and contain 2 * 10 4～4 * 10 4The suspension of individual cell.Obtained cell suspension is inoculated on 96 orifice plates, and every hole 180 μ L put constant temperature CO 2Cultivated 24 hours in the incubator.Change liquid, (compound dilutes with PBS with DMSO dissolving back, and test-compound concentration is respectively 1 * 10 to add test-compound -7, 1 * 10 -6, 1 * 10 -5Mol/L), every hole 20 μ L cultivated 48 hours.MTT is added in 96 orifice plates, every hole 20 μ L, reaction is 4 hours in the incubator.Supernatant liquor is removed in suction, adds DMSO, every hole 150 μ L, and jolting is 5 minutes on the dull and stereotyped shaking table.Is the optical density that the 570nm place measures every hole with enzyme-linked immunosorbent assay instrument at wavelength, calculates cell inhibitory rate.Experimental result is shown in table 3-4.
Cell inhibitory rate=(negative control group OD value-tried thing group OD value)/negative control group OD value * 100%.
Table 3 The compounds of this invention is to part tumor cell proliferation inhibition activity (IC 50, μ mol/L)
Figure GSA00000083319200091
Figure GSA00000083319200101
Sorafenib: Suo Lafeini; NA: non-activity.
Table 4 The compounds of this invention is to part tumor cell proliferation inhibition activity (IC 50, μ mol/L)
Figure GSA00000083319200102
Figure GSA00000083319200111
Sorafenib: Suo Lafeini; NA: non-activity.
Through the test of a series of tumour cells, find that these compounds are stronger to the kidney cancer cell effect, OS-RC-2 human renal carcinoma cell particularly, most of target compound cytoactive is stronger than lead compound FTA, a lot of Compound I C 50Value is all less than 1 μ mol/L, wherein Compound I 1, I 2, I 4, II 1, II 3, II 6, II 12, II 13, II 14Suo Lafeini is strong for the specific activity positive control drug, its IC 50Value is all less than 0.25 μ mol/L; From 786-O human renal carcinoma cell test case, I 1, I 4, II 12, II 13, II 14Cytoactive is all active strong than parent compound FTA, and quite active with positive control drug Suo Lafeini, and the majority of compounds activity is all above guide's thing FTA;
In human glioma cell U87 and U251, Compound I 2, II 12, II 13, II 14IC 50Value and Suo Lafeini are at an order of magnitude, and the majority of compounds activity is all above parent compound FTA;
For human breast cancer cell MCF7, Compound I 4, II 3, II 6, II 12Active quite active with positive control drug Suo Lafeini, and human breast cancer cell MDA-MB-231, Compound I 2, II 6, II 12, II 13Specific activity positive control drug Suo Lafeini is strong slightly or quite, the majority of compounds activity is all above parent compound FTA;
For human lung cancer cell A549, H460 and H520, whole compound activity trend comparison unanimity, compound is more weak at human lung cancer cell A549's specific activity H460 and H520, wherein Compound I 2, II 12And II 13Than positive control drug Suo Lafeini is strong slightly or quite, the majority of compounds activity is all above parent compound FTA;
For human liver cancer cell Hep3B, Compound I 2, II 3, II 6, II 12And II 13IC 50Value and Suo Lafeini are at an order of magnitude, and gastric carcinoma cells SGC-7901, I 2, II 12And II 13Than positive control drug Suo Lafeini is strong slightly or quite, the majority of compounds activity is all above parent compound FTA.
From the whole antitumor spectra of compound, in the FTA derivative series compound that the furazan oxynitride is modified, the amino acid whose furazan oxynitride overall activity of middle connection is better than not connecting amino acid active, and the amino acid whose kind of linking group is influential to activity, and the influence of its pair cell cytotoxic activity is proline(Pro)＞glycine, L-Ala＞phenylalanine in proper order.And for the compound that contains same amino acid, furazan oxynitride donor linking group carbon chain lengths influences activity equally, and is better with 4 carbon atoms.Such as all containing L-Ala but the different compound activity of company's carbochain be in proper order: II 6＞II 9＞II 5＞II 8
The pharmacological results shows, The compounds of this invention has in various degree restraining effect to human tumor cell's propagation, and most antitumor activity of compound and positive control drug Suo Lafeini quite or be better than Suo Lafeini and significantly are better than FTA.
1.2 influence to normal liver cell growth
Be subjected to the reagent thing
The FTA derivative series one active better target compound I that the furazan oxynitride is modified 1, I 2, I 4, II 1, II 3, II 6, II 12, II 13, II 14, alltrans farnesyl thiosalicylic acid (FTA) is medicine in contrast, totally 10 compounds.
Material, reagent and method
Method is the same, and people's normal liver cell is LO2, and nutrient solution is for containing 10% heat-inactivated fetal bovine serum, the RPMI1640 cell culture medium of penicillin 100u/mL and Streptomycin sulphate 100u/mL, and the drug treating time is 48 hours, concentration is chosen and is seen Fig. 7.
The result
The FTA derivative I that part furazan oxynitride is modified 2, II 12, II 6, I 4Under less than 12.5 μ mol/L (in effective inhibition concentration scope that the Hep3B cell is grown, seeing Fig. 7) concentration, there is not tangible LO2 cytotoxicity, visible significant cytotoxicity in the 25-100 μ mol/L concentration range.This shows I 2, I 4, II 6, II 12Liver cancer Hep3B cell is had certain selectivity, and selectivity order is I 2＞II 12＞II 6＞I 4, I wherein 2And II 12IC to people's normal liver cell LO2 50Value is than they IC to human liver tumor cell Hep3B 50Be worth big approximately two order of magnitude (see figure 1)s.
1.3 discharging, external NO detects
The select target Compound I 1, I 3, II 3, II 6And II 12～II 14In breast cancer cell MCF-7, MDA-MB-231, stomach cancer cell SGC-7901, lung cell A549 and brain cancer cell U251, U87, carry out the mensuration of NO burst size: get and be in one bottle in cell in good condition exponential phase of growth, add 0.25% tryptic digestion, attached cell is come off, make every milliliter and contain 2 * 10 4～4 * 10 4The suspension of individual cell.Obtained cell suspension is inoculated on 96 orifice plates, and every hole 180 μ L put constant temperature CO 2Cultivate 24h in the incubator.Change liquid, (compound dilutes with PBS with DMSO dissolving back, and being tried substrate concentration is 10-4mol/L to add test-compound.Get supernatant liquor 2mL and 500 μ LGriess reagent mix in the centrifugation of 300min time point, room temperature was placed 10 minutes, surveyed absorption value at the 540nm place, calculated NO concentration according to typical curve.The burst size of NO is equivalent to nitrate (NO with it 3 -)/nitrite (NO 2 -) scale show (see figure 2).
External NO releasing research result shows Compound I I 3, II 6And II 12～II 14Between the NO burst size be more or less the same, but compare I 1, I 3Much bigger, the maximum burst size of NO reaches 1.6 μ mol/L.Results suggest, it is relatively large that compound with cytotoxic activity discharges the amount of NO, and the amount that active compound more weak or non-activity discharges NO is lower, this result and document (Megson IL, WebbDJ.Expert Opin Investig Drugs, 2002,11 (5): 587-601) Bao Dao higher concentration NO is consistent to the conclusion that tumour cell has strong cytotoxicity.
1.4Ras inhibition active testing
Adopt the Western blotting to detect target compound II 6Ras to tumour cell MDA-MB-231 suppresses active.Get and be in exponential phase of growth cell in good condition and make every milliliter and contain 1.5 * 10 5The suspension of individual cell is inoculated on 96 orifice plates, puts constant temperature CO 2Cultivate 24h in the incubator.Change liquid, add 1 μ M, 5 μ M test-compound II 6, negative control adds equivalent PBS, continues to cultivate 8h.Trysinization, PBS cleans twice.Sample is resuspended among the PBS, abandons supernatant, and cell places 2mL EP pipe to add protein cleavage liquid, 200 μ L/ pipe, the piping and druming back is in ice bath reaction 30min repeatedly, and in the centrifuging and taking supernatant liquor 2mL EP pipe, employing SDS-PAGE (gum concentration is 12%) separates and transfers on the nitrocellulose membrane.Film is put in 5% the skim-milk confining liquid of now joining, and sealing finishes with a small amount of Blot wash that remaining milk powder rinsing is clean, and one anti-ly is diluted to working concentration with TBST, 500 μ L/ bars, and the room temperature shaking table reacts 1h, can put 4 ℃ thereafter and spend the night.Reaction is cut off valve bag after finishing, and discarded antibody places ware to clean 4 times with TBST each bar film.Resist to working fluid concentration 500 μ L/ bars with two of TBST dilution peroxidase mark.By preceding method envelope and shaking table reaction, abandon two after reaction finishes and resist, clean 4 times with TBST.PIERCE luminescent solution A liquid+B liquid equal-volume mixing pours in the valve bag that makes, and behind the reaction 5min film is transferred to exposure image (see figure 3) in BIO-RAD gel imaging instrument magazine.
We have investigated target compound II 6Whether keep the original Ras of FTA and suppress active, adopt the II of blank group and different concns 6The immunoblotting assay (see figure 3) is carried out in influence to the relevant Ras downstream signal path of MDA-MB-231 cell, finds II 6Under 1 μ M and 5 μ M concentration, can significantly suppress Akt, ERK, the phosphorylation of Raf molecule has still kept after prompting NO donor and the FTA heterozygosis Ras albumen has been suppressed active.
2, activity in vivo research
2.2I 2Acute toxicity test
Purpose
Mouse single intraperitoneal injection trial-product method is adopted in this experiment, observes chmice acute toxic reaction and death condition that trial-product causes.
Experiment material
Trial-product title: I 2(China Medicine University new drug research center provides).
Reference substance: i.e. solvent is dehydrated alcohol and glucose injection.
Animal
A cleaning level mouse, 5-6 age in week, body weight 18-22g, sex: male and female half and half.
Experimental technique
Dosage design and medicine configuration: according to pre-test result, official test dosage is made as 585.9,468.8,375.0,300.0 and 240.0mgg/kg, and the dosage spacing is 1: 0.8.Establish the solvent control group simultaneously.Medicine adds 20% anhydrous alcohol solution earlier, with the glucose injection dilution, gets the solution that final concentration is respectively 195.3mg/ml, 156.2mg/ml, 125.0mg/ml, 100mg/ml, 80mg/ml again.
Medication and approach: adopt the intraperitoneal injection approach.The administration of mouse once abdominal cavity injection, administration volume 0.6ml/20g body weight, abdominal injection speed 0.6ml/60Sec.
Detection method and data logging: the animal fasting is 2-4 hour before the administration.Detail record animals administer time, toxic reaction time and toxic reaction symptom.Calculate medium lethal dose LD according to animal dead The data Bliss method 50Value and 95% fiducial limit (seeing Table 5).
Experimental result
585.9mg/kg spasm, tic appear in 8 mouse after the administration of dosage group, wherein 2 death at once; 468.8mg/kg spasm, tic appear in 4 mouse after the administration of dosage group; 375.0/kg 2 movable minimizings of mouse after the administration of dosage group; 300.0mg/kg 1 movable minimizing of mouse after the administration of dosage group; Reduce 240.0mg/kg mouse is movable after the administration of dosage group, behavioral activity recovers normal gradually after 10 minutes.
Table 5, mouse peritoneal injection I 2The LD of solution 50Test-results
Figure GSA00000083319200141
2.2I 2Intraperitoneal administration is to the experimental therapy effect purpose of human liver cell liver cancer SMMC-7721 Nude Mice
According to the requirement of SFDA new drug preclinical study governing principle, test I 2People's liver cancer SMMC-7721 bare mouse different species transplanted tumor is had or not growth-inhibiting effect and action intensity.
Tried thing
The I2 injection liquid provides lot number by China Medicine University medicine research centre: 100117.Positive control drug is Suo Lafeini (Sorafenib), and Shanghai BeiKa Medicine Technology Co., Ltd produces, lot number: 091105.
Transplanted tumor
Select human liver cell liver cancer SMMC-7721 Nude Mice for use, it is subcutaneous and set up to be inoculated in nude mouse by human liver cell liver cancer SMMC-7721 cell strain.The cell inoculation amount is 2 * 10 7, inoculation is used after forming and passing for 3 generations again in the nude mouse body behind the transplanted tumor.
Animal
Female BALB/cA nude mouse, age in days 35-40 days, body weight 18-22g provided (laboratory animal production licence: SCXK (army) 2007-004) by Institute of Experimental Animals, Chinese Academy of Medical Sciences.Animal is grouped as follows:
12 of blank groups (solvent control)
6 of positive controls (FTA 16mg/kg i.p.)
6 of positive controls (Sorafenib 20mg/kg i.p.)
6 of medication therapy groups (I260mg/kg i.p.)
6 of medication therapy groups (I230mg/kg i.p.)
6 of medication therapy groups (I215mg/kg i.p.)
Test method
The tumor tissue of getting the growth animated period cuts into 1.5mm 3About, under aseptic condition, it is subcutaneous to be inoculated in nude mouse right side armpit.Nude Mice is treated tumor growth to 100～300mm with vernier caliper measurement transplanted tumor diameter 3After with the animal random packet.Use the method for measuring the knurl footpath, dynamic observe the antineoplastic effect of tested thing.The measurement number of times of diameter of tumor is that each the measurement also need claim mouse heavy simultaneously 3 times weekly.The administration group is intravenously administrable 3 times weekly, and administration volume 0.4mL/ only.Positive controls is intravenously administrable 3 times weekly, and negative control group is given equivalent physiological saline simultaneously.
Detect index and method of calculation
(1) gross tumor volume (tumor volume, TV), calculation formula is:
TV＝1/2×a×b 2
Wherein a, b represent length and width respectively.
(2) relative tumour volume (relative tumor volume, RTV), calculation formula is:
RTV＝TV t/TV 0。
TV wherein 0(d during for minute cage administration 0) gross tumor volume, TV tGross tumor volume when measuring each time.
(3) relative tumor proliferation rate T/C (%), calculation formula is:
T/C(％)＝(T RTV/C RTV)×100
T RTV: treatment group RTV; C RTV: negative control group RTV.
Test-results is with the evaluation index of relative tumor proliferation rate T/C (%) as anti-tumor activity.
Experimental result and discussion:
I2 sees Table 6 and Fig. 4 to the experimental treatment result of people's liver cancer SMMC-7721 Nude Mice.Experimental result is as follows, medicine I to be measured 2(60mg/kg), I 2(30mg/kg), I 2(15mg/kg), positive drug FTA (16mg/kg), Sorafenib (20mg/kg) are all with intraperitoneal injection, and every day 1 time, administration is 21 times altogether; After the administration 21 days, administration is after 21 days, and the average knurl volume of blank group is 1378mm 3, the average knurl volume of FTA control group is 664mm 3, the Sorafenib group is 397mm 3, I 2High dose group is 479mm 3, I 2Middle dosage group is 732mm 3, I 2Low dose group is 793mm 3, the T/C (%) of people's liver cancer SMMC-7721 Nude Mice is respectively 59.56%, 28.46%, 43.38%, 52.56%, 58.95%.Do not find simultaneously I 2Body weight to laboratory animal has obvious restraining effect.
Table 6.I 2Influence (X ± SD, gross tumor volume: the mm of unit to transplanted tumor in nude mice SMMC-7721 growth volume change 3)
Figure GSA00000083319200161
Description of drawings
Fig. 1 .I2, I4, II6, II12 is to the selectivity of liver cancer Hep3B cell and people's normal liver cell LO2
Fig. 2 part of compounds NO in tumour cell discharges
Fig. 3 II 6Ras to tumour cell MDA-MB-231 suppresses active
Fig. 4 .I 2Influence to people's liver cancer SMMC-7721 bare mouse different species transplantation tumor gross tumor volume
Embodiment
In order further to illustrate the present invention, provide a series of embodiment below, these embodiment are illustrative fully, they only are used for the present invention is specifically described, and not should be understood to limitation of the present invention.The used FTA of the present invention is a prepared in laboratory, content＞98%.
Embodiment 1
2-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of ethamine (1a)
With 3mL (50mmol) thanomin and 1.85g (5mmol) 2-oxygen-3; 4-two benzenesulfonyls-1; 2; the 5-oxadiazole is dissolved among the 20mLTHF, and the ice bath cooling splashes into 2.5mol/LNaOH solution 2mL; room temperature reaction 0.5h; add 2.5mol/LNaOH solution 1mL, it is complete until raw material reaction to continue stirring, pours 80mL water into; methylene dichloride (3 * 20mL) extractions; the saturated common salt water washing, anhydrous sodium sulfate drying concentrates; the methanol recrystallization; white solid (1a) 0.93g, yield 66%, mp:102～104 ℃.
N-{2-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] ethyl } farnesyl thiosalicylic acid acid amides (I 1) preparation
18.0g (0.50mmol) FTA and 14.0mg (0.65mmol) DCC are dissolved in the anhydrous CH of 15mL 2Cl 2In, stirring at room 30 minutes, the DMAP of adding 0.18g (0.60mmol) 1a and catalytic amount, room temperature reaction 24 hours, filter, concentrate, column chromatography [ethyl acetate: sherwood oil (60～90 ℃)=1: 3 (V: V)] separate water white transparency oily thing 0.21g, yield 67%, IR (KBr, cm -1) v:2922,1713,1654,1618,1551,1454,1374,1164; 1H NMR (CDCl 3, 300MHz): δ 8.02 (d, 2H, J=7.8Hz, Ar-H), 7.70 (m, 2H, Ar-H), 7.55 (t, 2H, J=7.8Hz, Ar-H), 7.36 (m, 2H, Ar-H), 7.18 (m, 1H, Ar-H), 7.20 (m, 1H, Ar-H), 5.25 (m, 1H, SCH 2C H), 5.08 (m, 2H, 2 * CH 2C H=CCH 3), 4.64 (t, 2H, J=4.8Hz, C H 2O), 3.96 (m, 2H, NC H 2CH 2), 3.53 (d, 2H, J=7.2Hz, SC H 2), 3.35 (m, 1H, NC H 2), 1.89-2.02 (m, 8H, 2 * CHC H 2C H 2CH), 1.50-1.68 (m, 12H, 4 * CH=CC H 3); ESI-MS (m/z): 626[M+H] +.
Embodiment 2
N-{[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group } preparation of piperazine (1b)
Preparation method with reference to 1a makes faint yellow solid by hydroxyethyl piperazine, yield 55%, mp:90～92 ℃.
3-{4-[3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] propoxy-]-1,4-dioxo butoxy } farnesyl thio-methyl salicylate (I 2) preparation
N-{[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group } the inferior acid amides (I of piperazinyl farnesyl thiosalicylic acid 2) preparation
With reference to I 1The preparation method, make water white transparency oily thing, yield 61% by FTA and 1b reaction.IR(KBr，cm -1)v：2926，1731，1648，1551，1454，1371，1167； 1H?NMR(CDCl 3，300MHz)：δ8.05(d，2H，J＝7.8Hz，Ar-H)，7.75(m，1H，Ar-H)，7.61(m，2H，Ar-H)，7.38(m，H，Ar-H)，7.28(m，3H，Ar-H)，5.28(m，1H，SCH 2C H)，5.08(m，2H，2×CH 2C H＝CCH 3)，4.58(t，2H，J＝5.1Hz，C H 2O)，3.84(d，2H，J＝4.5Hz，NCH 2)，3.56(m，2H，SCH 2)，2.91(m，4H，CONC H 2C H 2)，2.63(m，4H，2×C H 2NC H 2)，1.89-2.04(m，8H，2×CHC H 2C H 2CH)，1.50-1.67(m，12H，4×CH＝CC H 3)；ESI-MS(m/z)：695[M+H] +；
Embodiment 3
4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)]-preparation of 2-butyne-1-alcohol (1c)
With reference to the preparation method of 1a, make white solid by the 2-butyne glycol, yield 63%, mp:110～112 ℃.
4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)]-the 2-alkynyl } farnesyl thiosalicylic acid butyl ester (I 3) preparation
With reference to I 1The preparation method, make water white transparency oily thing, yield 65%, IR (KBr, cm by FTA and 1c reaction -1) v:2934,1724,1618,1548,1453,1357,1167; 1H NMR (CDCl 3, 300MHz): δ 8.06 (d, 2H, J=7.8Hz, Ar-H), 8.01 (d, 1H, J=7.8Hz, Ar-H), 7.74 (t, 1H, J=7.2Hz, Ar-H), 7.62 (m, 2H, Ar-H), 7.47 (t, 1H, Ar-H), 7.33 (m, 1H, Ar-H), 7.20 (m, 1H, Ar-H), 5.33 (m, 1H, SCH 2C H), 5.12 (m, 4H, 2 * CH 2C H=CCH 3, COOCH 2), 5.00 (s, 2H, OCH 2), 3.60 (d, 2H, J=7.2Hz, SC H 2), 1.88-2.04 (m, 8H, 2 * CHC H 2C H 2CH), 1.48-1.68 (m, 12H, 4 * CH=CC H 3); ESI-MS (m/z): 651[M+H] +.
Embodiment 4
4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of piperidines (1d)
With reference to the preparation method of 1a, make white solid by the 4-hydroxy piperidine, yield 79%, mp:70～72 ℃.
N-{4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] piperidyl } the inferior acid amides (I of farnesyl thiosalicylic acid 4) preparation
With reference to I 1The preparation method, make water white transparency oily thing, yield 68%, IR (KBr, cm by FTA and 1d reaction -1) v:2932,1721,1616,1553,1453,1371,1165; H NMR (CDCl 3, 300MHz): δ 8.05 (m, 2H, Ar-H), 7.77 (t, 1H, J=7.2Hz, Ar-H), 7.63 (m, 2H, Ar-H), 7.40 (m, H, Ar-H), 7.26 (m, 3H, Ar-H), 5.27 (m, 1H, SCH 2CH), 5.18 (m, 2H, 2 * CH 2C H=CCH 3), 5.08 (m, 1H, OCH), 3.88 (m, 2H, SC H 2), 3.47 (m, 4H, N (CH 2) 2), 1.89-2.02 (m, 12H, 2 * CHC H 2C H 2CH, CH (CH 2) 2), 1.50-1.68 (m, 12H, 4 * CH=CC H 3); ESI-MS (m/z): 666[M+H] +.
Embodiment 5
3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of propylamine (1e)
Preparation method with reference to 1a makes white solid by Propanolamine, yield 70%, mp:57～59 ℃.
N-{3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] propyl group } farnesyl thiosalicylic acid acid amides (I 5) preparation
With reference to I 1The preparation method, make water white transparency oily thing, yield 67%, IR (KBr, cm by FTA and 1e reaction -1) v:2952,1733,1656,1616,1552,1434,1386,1164; 1H NMR (CDCl 3, 300MHz): δ 8.00 (d, 2H, J=7.5Hz, Ar-H), 7.74 (t, 1H, J=7.5Hz, Ar-H), 7.61 (m, 3H, Ar-H), 7.40 (m, 2H, Ar-H), 7.30 (m, 1H, Ar-H), 5.26 (m, 1H, SCH 2C H), 5.07 (m, 2H, 2 * CH 2C H=CCH 3), 4.59 (t, 2H, J=6.0Hz, OC H 2), 3.71 (d, 2H, J=7.8Hz, SC H 2), 3.55 (d, 2H, J=7.5Hz, NCH 2), 2.26 (m, 2H, NCH 2C H 2), 1.89-2.02 (m, 8H, 2 * CHC H 2C H 2CH), 1.50-1.68 (m, 12H, 4 * CH=CC H 3); ESI-MS (m/z): 630[M+H] +
Embodiment 6
N-methyl-2-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of ethamine (2f)
With reference to the preparation method of 1a, make white solid by the N Mono Methyl Ethanol Amine, yield 50% directly drops into next step reaction.N-{N-methyl-2-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] ethyl } the inferior acid amides (I of farnesyl thiosalicylic acid 6) preparation
With reference to I 1The preparation method, make water white transparency oily thing, yield 65%, IR (KBr, cm by FTA and 2c reaction -1) v:2956,1733,1618,1454,1359,1157; 1H NMR (CDCl 3, 300MHz): δ 8.07 (d, J=7.5Hz, 2H, Ar-H), 7.94 (m, 1H, Ar-H), 7.76 (m, 1H, Ar-H), 7.59 (m, 3H, Ar-H), 7.31 (m, 2H, Ar-H), 5.30 (m, 1H, SCH 2C H), 5.07 (m, 2H, 2 * CH 2C H=CCH 3), 4.77 (m, 2H, OC H 2), 4.06 (d, 2H, J=7.8Hz, SC H 2), 3.53 (m, 2H, NCH 2), 3.02 (m, 3H, NCH 3), 1.89-2.02 (m, 8H, 2 * CHC H 2C H 2CH), 1.50-1.68 (m, 12H, 4 * CH=CC H 3); ESI-MS (m/z): 630[M+H] +
Embodiment 7
1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of propyl alcohol (1g)
Preparation method with reference to 1a makes white solid by 1,3 butylene glycol, yield 88%, mp:101～103 ℃.
1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] } farnesyl thiosalicylic acid propyl ester (I 7) preparation
With reference to I 1The preparation method, make water white transparency oily thing, yield 65%, IR (KBr, cm by FTA and 1g reaction -1) v:2947,1730,1616,1552,1454,1380,1164; 1H NMR (CDCl 3, 300MHz): δ 8.08 (d, 2H, J=7.8Hz, Ar-H), 7.93 (d, 1H, J=7.5Hz, Ar-H), 7.73 (m, 1H, Ar-H), 7.64 (m, 2H, Ar-H), 7.43 (t, 1H, J=7.2Hz, Ar-H), 7.30 (m, 1H, Ar-H), 7.16 (m, 1H, Ar-H), 5.40 (m, 1H, SCH 2C H), 5.31 (m, 2H, OC H), 5.08 (m, 2H, 2 * CH 2C H=CCH 3), 4.56 (t, 2H, J=6.0Hz, OC H 2), 3.56 (d, 2H, J=7.2Hz, SC H 2), 2.28 (m, 2H, CHC H 2), 1.89-2.02 (m, 8H, 2 * CHC H 2C H 2CH), 1.50-1.68 (m, 12H, 4 * CH=CC H 3), 1.47 (d, 3H, J=6.3Hz, CHC H 3); ESI-MS (m/z): 655[M+H] +
Embodiment 8
2-{[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] methoxyl group } preparation of tetramethyleneimine (1h)
With reference to the preparation method of 1a, make faint yellow solid by L-dried meat ammonia alcohol, yield 88% directly carries out next step reaction.
N-{2-{[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] methoxyl group } pyrrolidyl } the inferior acid amides (I of farnesyl thiosalicylic acid 8) preparation
With reference to I 1The preparation method, make water white transparency oily thing, yield 65% by FTA and 1h reaction.IR(KBr，cm -1)v：2933，1730，1616，1552，1454，1380，1164； 1H?NMR(CDCl 3，300MHz)：δ8.05(m，2H，Ar-H)，7.93(m，1H，Ar-H)，7.76(m，1H，Ar-H)，7.61(m，2H，Ar-H)，7.43(t，1H，J＝7.2Hz，Ar-H)，7.39(m，1H，Ar-H)，7.29(m，1H，Ar-H)，5.19(m，1H，SCH 2C H)，5.07(m，2H，2×CH 2C H＝CCH 3)，4.90(m，1H，NCH)，4.65(m，2H，OC H 2)，3.51(d，2H，J＝7.8Hz，SC H 2)，3.30(m，2H，NCH 2)，1.89-2.02(m，8H，2×CHC H 2C H 2CH)，1.50-1.68(m，12H，4×CH＝CC H 3)，1.50-1.67(m，4H，CHCH 2CH 2)；ESI-MS(m/z)：666[M+H] +；
Embodiment 9
2-{[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] ethylamino-} preparation of ethanol (1i)
Preparation method with reference to 1a makes faint yellow solid by diethanolamine, and yield 65% directly drops into next step reaction.
The preparation of N-hydroxyethyl { N-[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] ethyl } the carbonic acid tert-butyl ester (1i-1)
At the anhydrous CH of the 10mL of 0.33g (1.00mmol) 1i and 0.2mL triethylamine 2Cl 2In, slowly adding 0.26g (1.20mmol) tert-Butyl dicarbonate, stirred overnight at room temperature extracts CH with 10mL water and saturated NaCl respectively with reaction solution 2Cl 2Layer is used anhydrous sodium sulfate drying, is spin-dried for to obtain 0.39g product 1i-1 and directly cast single step reaction, yield 91%.
2-{N-tertbutyloxycarbonyl-2-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] ethylamino-} farnesyl thiosalicylic acid ethyl ester (I 9) preparation
With reference to I 1The preparation method, make water white transparency oily thing, yield 70%, mp:82～84 ℃ by FTA and 1i-1 reaction.IR(KBr，cm -1)v：2952，1728，1618，1550，1452，1352，1164； 1H-NMR(300MHz，CDCl 3)δ：8.05(d，2H，J＝8.1Hz，Ar-H)，7.70(m，1H，Ar-H)，7.58(m，2H，Ar-H)，7.40(m，2H，Ar-H)，7.23(m，2H，Ar-H)，5.24(t，1H，J＝7.5Hz，SCH 2C H)，5.06(t，2H，J＝6.9Hz，2×CH 2C H＝CCH 3)，4.35(m，2H，OC H 2)，3.84(m，2H，OC H 2)，3.73(m，4H，C H 2NC H 2)，3.58(d，2H，J＝7.2Hz，SC H 2)，1.89-2.02(m，8H，2×CHC H 2C H 2CH)，1.50-1.68(m，12H，4×CH＝CC H 3)；1.38(s，9H，3CH 3)；ESI-MS(m/z)：870[M+H] +.
Embodiment 10
2-{[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] ethylamino-} farnesyl thiosalicylic acid ethyl ester (I 10) preparation
With previous step product 0.38g (0.50mmol) I 9Be dissolved in 4mL CH 2Cl 2In, the ice bath cooling slowly drips the 2mL trifluoroacetic acid, rises to room temperature, and reaction 2h removes solvent and unreacted trifluoroacetic acid under reduced pressure, adds 10mL CH again 2Cl 2, slowly drip the 1.5mL triethylamine, drip off and stir 30min, reaction solution is washed CH with 10mL water and saturated NaCl respectively 2Cl 2Layer is used anhydrous sodium sulfate drying, is spin-dried for and obtains the 0.39g product I 10Water white transparency oily thing 0.42g, yield 62.8%.IR(KBr，cm -1)v：2958，1731，1652，1622，1552，1454，1377； 1H?NMR(CDCl 3，300MHz)：δ7.96(d，1H，J＝7.8Hz，Ar-H)，7.91(d，2H，J＝7.2Hz，Ar-H)，7.62(t，1H，J＝7.5Hz，Ar-H)，7.49(m，2H，Ar-H)，7.30(m，2H，Ar-H)，7.16(m，1H，Ar-H)，6.22(brs，1H，NH)，5.33(m，3H，SCH 2C H，2×CH 2C H＝CCH 3)，4.37(m，4H，C H 2O)，3.73(m，4H，C H 2NHC H 2)，3.58(d，2H，J＝7.2Hz，SC H 2)，1.89-2.02-(m，8H，2×CHC H 2C H 2CH)，1.50-1.68(m，12H，4×CH＝CC H 3)；ESI-MS(m/z)：770[M+H] +.
Embodiment 11
N-{N-[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] hydroxyethyl } farnesyl thiosalicylic acid ethanamide (I 11) preparation
0.36g (1.00mmol) FTA is dissolved in the anhydrous CH of 10mL 2Cl 2In, dripping the 0.5mL oxalyl chloride, room temperature reaction 4h removes solvent under reduced pressure and unreacted gets oxalyl chloride, again with the farnesyl sulfo-bigcatkin willow acyl chlorides of the making anhydrous CH of 10mL 2Cl 2Dissolving slowly splashes into the anhydrous CH of 10mL that contains 0.33g (1.00mmol) 1i and 0.2mL triethylamine under ice bath 2Cl 2In, at stirring at room 12h, filter, concentrate, column chromatography [ethyl acetate: sherwood oil (60～90 ℃)=1: 5 (V: V)] separate water white transparency oily thing 0.42g, yield 62.8%.IR(KBr，cm -1)v：2958，1731，1652，1622，1552，1454，1377； 1H?NMR(CDCl 3，300MHz)：8.05(d，2H，J＝8.1Hz，Ar-H)，7.70(m，1H，Ar-H)，7.58(m，2H，Ar-H)，7.40(m，2H，Ar-H)，7.23(m，2H，Ar-H)，5.25(t，1H，J＝6.6Hz，SCH 2C H)，5.06(m，4H，2×CH 2C H＝CCH 3，NC H 2)，4.55(m，2H，OC H 2)，4.12(m，1H，OH)3.84(m，2H，HOC H 2)，3.15(m，2H，NCH 2)，3.54(d，2H，J＝7.2Hz，SC H 2)，2.92(t，2H，J＝5.1Hz，HOCH 2C H 2)，1.89-2.00(m，8H，2×CHC H 2C H 2CH)，1.51-1.65(m，12H，4×CH＝CC H 3)；ESI-MS(m/z)：770[M+H] +.
Embodiment 12
N-Boc-glycine-1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of propyl ester (3-1g)
0.37g (1.1mmol) 1g is dissolved in the anhydrous CH of 15mL 2Cl 2In, add 0.18g (1.0mmol) N-t-butoxycarbonyl glycine, 0.26g (1.25mmol) DMAP of DCC and catalytic amount, room temperature reaction 24h, filter, concentrate, column chromatography [ethyl acetate: sherwood oil (60～90 ℃)=1: 3 (V: V)] separate white solid 0.29g, yield 60%, mp:84～86 ℃.ESI-MS(m/z)：471.6[M+H] +；IR(KBr，cm -1)v：3436，2977，2937，1747，1714，1616，1552，1514，1452，1367，1166； 1H-NMR(300MHz，CDCl 3)δ：1.35～1.37(m，3H，CH 3，)，1.43(s，9H，3CH 3)，3.89～3.90(d，2H，NCH 2)，4.46～4.50(t，2H，OCH 2，J＝6.0Hz)，5.01(brs，1H，NH)，5.19～5.25(m，1H，OCH)，7.60～7.66(m，2H，ArH)，7.74～7.76(m，1H，ArH)，8.05～8.08(m，2H，ArH).
Glycine-1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of propyl ester trifluoroacetate (4-1g)
0.25g (0.52mmol) 3-1g is dissolved in 10mL CH 2Cl 2In, the ice bath cooling slowly drips the 2mL trifluoroacetic acid, rises to room temperature, and reaction 2h removes solvent and unreacted trifluoroacetic acid under reduced pressure, obtains 4-1g, ESI-MS (m/z): 372.1[M+H] +
N-{ acetate-1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] propyl ester } farnesyl thiosalicylic acid acid amides (II 1) preparation
The 4-1g of above-mentioned preparation is dissolved among the 15mL DMF, adds 0.20g (1.60mmol) DMAP, stirred 30 minutes, add 0.20g (0.43mmol) FTA, 0.25g (1.30mmol) EDC, room temperature reaction 24h, impouring 200mL water, (3 * 50mL) extractions merge organic layer to ethyl acetate, the saturated common salt washing, anhydrous sodium sulfate drying filters, concentrate, column chromatography [ethyl acetate: sherwood oil (60～90 ℃)=1: 2 (V: V)] separate, get water white transparency oily thing 0.15g, yield 45%.IR(KBr，cm -1)：3424，2927，1753，1629，1552，1450，1371，1168； 1H?NMR(CDCl 3，300MHz)：δ8.05(d，2H，J＝8.1Hz，Ar-H)，7.70(m，1H，Ar-H)，7.58(m，2H，Ar-H)，7.40(m，2H，Ar-H)，7.29(m，2H，Ar-H)，5.25(t，1H，J＝6.6Hz，SCH 2C H)，5.06(m，4H，2×CH 2C H＝CCH 3，NC H 2)，4.48(t，2H，J＝6.0Hz，C H 2O)，4.25(m，1H，OC H)，3.54(d，2H，J＝7.5Hz，SC H 2)，2.20(m，2H，OCHC H 2)，1.98-2.05(m，8H，2×CHC H 2C H 2CH)，1.51-1.68(m，12H，4×CH＝CC H 3)，1.39(d，3H，J＝6.3Hz，CHC H 3)；MS(ESI)m/z＝712[M+1] +.
Embodiment 13
4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of butanols (1j)
With reference to the preparation method of 1a, by 1, the 4-butyleneglycol makes white solid, yield 89%, mp:70～72 ℃.
N-Boc-glycine-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of butyl ester (3-1j)
Preparation method with reference to 3-1g makes white solid by 1j, yield 78%, mp:60～62 ℃.ESI-MS(m/z)：471.8[M+H] +；IR(KBr，cm -1)v：3357，2977，2933，1726，1685，1623，1558，1525，1454，1371，1163； 1H-NMR(300MHz，CDCl 3)δ：1.45(s，9H，3CH 3)，1.85～1.87(m，2H，CH 2)，1.95～1.99(m，2H，CH 2)，3.92～3.94(d，2H，NCH 2)，4.23～4.27(t，2H，OCH 2，J＝6.0Hz)，4.44～4.48(t，2H，OCH 2，J＝6.0Hz)，5.06(brs，1H，NH)，7.61～7.66(m，2H，ArH)，7.77～7.79(m，1H，ArH)，8.04～8.07(m，2H，ArH).
Glycine-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of butyl ester trifluoroacetate (4-1j)
Preparation method with reference to 4-1g is made by 3-1j, ESI-MS (m/z): 372.4[M+H] +
N-{ acetate-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] butyl ester } farnesyl thiosalicylic acid acid amides (II 2) preparation
With reference to II 1The preparation method, make water white transparency oily thing, yield 50%, IR (KBr, cm by FTA and 4-1j reaction -1): 3259,2928,1727,1621,1559,1450,1163; 1H NMR (CDCl 3, 300MHz): δ 8.04 (d, 2H, J=7.2Hz, Ar-H), 7.73 (m, 2H, Ar-H), 7.58 (m, 2H, Ar-H), 7.36 (m, 2H, Ar-H), 7.27 (m, 1H, Ar-H), 5.24 (t, 1H, J=7.5Hz, SCH 2C H), 5.06 (t, 2H, J=6.9Hz, 2 * CH 2C H=CCH 3), 4.79 (m, 2H, NC H 2), 4.45 (t, 2H, J=6.0Hz, COOCH 2CH 2CH 2C H 2O), 4.28 (m, 4H, NC H 2COOC H 2CH 2), 3.55 (d, 2H, J=7.5Hz, SC H 2), 1.99 (m, 10H, 2 * CHC H 2C H 2CH, COOCH 2CH 2C H 2), 1.51-1.69 (m, 14H, 4 * CH=CC H 3, COOCH 2C H 2); MS (ESI) m/z=712[M+1] +.
Embodiment 14
N-Boc-glycine-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)]-preparation of 2-alkynes-butyl ester (3-1c)
Preparation method with reference to 3-1g makes white solid by 1c, yield 68%, mp:88～90 ℃.IR(KBr，cm -1)v：3434，2979，1758，1704，1620，1548，1450，1359，1163； 1H-NMR(300MHz，DMSO-d6)δ：1.38(s，9H，3CH 3)，3.70～3.75(m，2H，NCH 2)，4.88(s，2H，OCH 2)，5.22(s，2H，OCH 2)，7.28(brs，1H，-NH-)，7.73～7.75(m，2H，ArH)，7.88～7.93(m，1H，ArH)，8.00～8.03(m，2H，ArH)；ESI-MS(m/z)：467.9[M+H] +.
Glycine-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)]-preparation of 2-alkynes-butyl ester trifluoroacetate (4-1c)
Preparation method with reference to 4-1g is made by 3-1c, ESI-MS (m/z): 368.3[M+H] +.
N-{ acetate-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)]-2-alkynes-butyl ester } farnesyl thiosalicylic acid acid amides (II 3) preparation
With reference to II 1The preparation method, make water white transparency oily thing, yield 55%, IR (KBr, cm by FTA and 4-1c reaction -1): 3418,2928,1758,1617,1548,1451,1361,1169; 1H NMR (CDCl 3-d 6): δ 8.06 (d, 2H, J=7.5Hz, Ar-H), 7.74 (m, 2H, Ar-H), 7.61 (t, 2H, J=7.5Hz, Ar-H), 7.30 (m, 3H, Ar-H), 5.24 (m, H, SCH 2C H), 5.06 (m, 4H, 2 * CH 2CH 2C H=CCH 3, C H 2O), 4.86 (s, 2H, COOC H 2), 4.31 (d, 2H, J=5.4Hz, NC H 2), 3.55 (d, H, J=7.8Hz, SCH 2), 1.98-2.12 (m, 8H, 2 * CHC H 2C H 2CH), 1.42-1.67 (m, 12H, 4 * CH 3); MS (ESI) m/z=708[M+1] +.
Embodiment 15
N-Boc-glycine-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of ethanamide (3-1a)
With reference to the preparation method of 3-1g, make white solid, yield 50.2%, mp:107～111 ℃ by 1a reaction.
N-{ acetate-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] ethanamide } farnesyl thiosalicylic acid acid amides (II 4) preparation
With reference to II 1The preparation method, make water white transparency oily thing, yield 49.4%, IR (KBr, cm with FTA reaction behind the 3-1a deprotection base -1) v:3406,2927,1724,1654,1550,1452,1388,1186; 1H NMR (CDCl 3, 300MHz): δ 8.04 (d, 2H, J=7.2Hz, Ar-H), 7.73 (m, 2H, Ar-H), 7.58 (m, 2H, Ar-H), 7.36 (m, 2H, Ar-H), 7.27 (m, 1H, Ar-H), 6.64 (m, 1H, CONH), 5.24 (t, 1H, J=7.5Hz, SCH 2C H), 5.06 (t, 2H, J=6.9Hz, 2 * CH 2C H=CCH 3), 4.52 (m, 2H, OCH 2), 4.28 (m, 4H, NC H 2, COOC H 2CH 2), 3.55 (d, 2H, J=7.5Hz, SC H 2), 1.99 (m, 8H, 2 * CHC H 2C H 2CH), 1.51-1.69 (m, 12H, 4 * CH=CC H 3); ESI-MS (m/z): 683[M+H] +
Embodiment 16
N-Boc-L-L-Ala-1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of propyl ester (3-2g)
With reference to the preparation method of 3-1g, make white solid, yield 72.3%, mp:98～101 ℃ by N-tert-butoxycarbonyl-l-alanine and 1g reaction.
N-{2-propionic acid-1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] propyl ester } farnesyl thiosalicylic acid acid amides (II 5) preparation
With reference to II 1The preparation method, make water white transparency oily thing, yield 41%, [α] with FTA reaction behind the 3-2g deprotection base 25 D:-8.1; IR (KBr, cm -1): 3297,2924,1737,1633,1555,1450,1356,1168; 1H NMR (CDCl 3-d 6): δ 8.06 (d, 2H, J=7.8Hz, Ar-H), 7.71 (m, 2H, Ar-H), 7.59 (m, 2H, Ar-H), 7.51 (m, 1H, Ar-H), 7.38 (m, 2H, Ar-H), 5.18 (m, 2H, SCH 2C H, NC H), 5.08 (m, 2H, 2 * CH 2C H=CCH 3), 4.74 (m, 1H, OC H), 4.46 (t, 2H, J=6.0Hz, OC H 2CH 2), 3.54 (d, 2H, J=7.5Hz, SC H 2), 2.17 (m, 2H, OCH 2C H 2), 1.98 (m, 8H, 2 * CHC H 2C H 2CH), 1.59-1.67 (m, 12H, 4 * CH=CC H 3), 1.51 (d, 2H, J=7.2Hz, NCHC H 3), 1.38 (d, 2H, J=6.0Hz, OCHC H 3); MS (ESI) m/z=726[M+1] +.
Embodiment 17
2-{[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group } preparation of ethanol (1k)
With reference to the preparation method of 1a, make white solid by a condensed ethandiol, yield 70%, mp:57～59 ℃.
N-Boc-L-L-Ala-2-{[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group } preparation of ethyl ester (3-2k)
With reference to the preparation method of 3-1g, make faint yellow solid, yield 53.3%, mp:127～129 ℃ by N-tert-butoxycarbonyl-l-alanine and 1k reaction.
N-{2-propionic acid-2-[[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group] ethyl ester } farnesyl thiosalicylic acid acid amides (II 6) preparation
With reference to II 1The preparation method, make water white transparency oily thing, yield 52.8%, [α] with FTA reaction behind the 3-2k deprotection base 15 D:-19.2; IR (KBr, cm -1): 3421,2928,1739,1640,1614,1554,1452,1356,1168; 1H NMR (CDCl 3, 300MHz): δ 8.04 (d, 2H, J=7.8Hz, Ar-H), 7.70 (m, 2H, Ar-H), 7.59 (m, 3H, Ar-H), 7.34 (m, 2H, Ar-H), 5.27 (t, 1H, J=7.2Hz, SCH 2C H), 5.05 (m, 2H, 2 * CH 2C H=CCH 3), 4.84 (m, 1H, NC H), 4.54 (m, 2H, COOCH 2CH 2OCH 2C H 2O), 4.38 (m, 2H, COOC H 2CH 2), 3.93 (m, 2H, COOCH 2CH 2OC H 2), 3.83 (t, 2H, J=4.2Hz, COOCH 2C H 2), 3.54 (d, 2H, J=7.8Hz, SC H 2), 2.01 (m, 8H, 2 * CHC H 2C H 2CH), 1.52-1.67 (m, 12H, 4 * CH=CCH 3), 1.38 (d, 3H, J=7.5Hz, NCHC H 3); MS (ESI) m/z=742[M+1] +.
Embodiment 18
N-Boc-L-proline(Pro)-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of butyl ester (3-3j)
With reference to the preparation method of 3-1g, make faint yellow oily thing, yield 60.2% by Boc-L-proline(Pro) and 1j reaction.
N-{2-Pyrrolidine formic acid-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] butyl ester } the inferior acid amides (II of farnesyl thiosalicylic acid 7) preparation
With reference to II 1The preparation method, make water white transparency oily thing, yield 34.8%, [α] with FTA reaction behind the 3-3j deprotection base 24 D:-14.5; IR (KBr, cm -1): 3437,2926,1743,1619,1552,1449,1365,1169; 1H NMR (CDCl 3, 300MHz): δ 8.04 (d, 2H, J=7.5Hz, Ar-H), 7.75 (m, 1H, Ar-H), 7.60 (m, 2H, Ar-H), 7.34 (m, 1H, Ar-H), 7.32 (m, 2H, Ar-H), 7.20 (m, 1H, Ar-H), 5.27 (t, 1H, J=7.5Hz, SCH 2C H), 5.05 (t, 2H, J=5.1Hz, 2 * CH 2C H=CCH 3), 4.67 (m, 1H, NC H), 4.47 (t, 2H, J=6.0Hz, COOCH 2CH 2CH 2C H 2O), 4.29 (m, 2H, COOC H 2CH 2), 3.57 (d, 2H, J=7.8Hz, SC H 2), 3.35 (m, 1H, NC H 2), 2.02 (m, 10H, C H 2CHCOO, 2 * CHC H 2C H 2CH), 1.90 (m, 2H, COOCH 2CH 2C H 2), 1.53-1.67 (m, 16H, 4 * CH=CC H 3, COOCH 2C H 2, NCH 2C H 2); MS (ESI) m/z=752[M+1] +.
Embodiment 19
N-Boc-L-L-Ala-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of butyl ester (3-2j)
With reference to the preparation method of 3-1g, make white solid, yield 61.9%, mp:107～109 ℃ by N-tert-butoxycarbonyl-l-alanine and 1j reaction.
N-{2-propionic acid-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] butyl ester } farnesyl thiosalicylic acid acid amides (II 8) preparation
With reference to II 1The preparation method, make water white transparency oily thing, yield 51.7%, [α] with FTA reaction behind the 3-2j deprotection base 24 D:-3.9; IR (KBr, cm -1): 3262,2927,1730,1625,1555,1450,1372,1167; 1H NMR (CDCl 3, 300MHz): δ 8.04 (d, 2H, J=7.5Hz, Ar-H), 7.69 (m, 2H, Ar-H), 7.60 (m, 2H, Ar-H), 7.54 (d, 1H, J=6.6Hz, Ar-H), 7.41 (d, 1H, J=7.8Hz, Ar-H), 7.29 (m, 1H, Ar-H), 5.24 (t, 1H, J=7.5Hz, SCH 2C H), 5.05 (t, 2H, J=6.9Hz, 2 * CH 2C H=CCH 3), 4.79 (m, 1H, NC H), 4.44 (t, 2H, J=6.0Hz, COOCH 2CH 2CH 2C H 2O), 4.26 (t, 2H, J=6.0Hz, COOC H 2CH 2), 3.54 (d, 2H, J=7.8Hz, SC H 2), 1.99 (m, 8H, 2 * CHC H 2C H 2CH), 1.88 (m, 2H, COOCH 2CH 2C H 2), 1.51-1.69 (m, 17H, 4 * CH=CC H 3, COOCH 2C H 2, NCHC H 3); MS (ESI) m/z=726[M+1] +.
Embodiment 20
N-Boc-L-L-Ala-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)]-preparation of 2-alkynes-butyl ester (3-2c)
With reference to the preparation method of 3-1g, make yellow solid, yield 53.7%, mp:113～115 ℃ by N-tert-butoxycarbonyl-l-alanine and 1c reaction.
N-[2-propionic acid-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)]-2-alkynes-butyl ester] farnesyl thiosalicylic acid acid amides (II 9) preparation
With reference to II 1The preparation method, make with FTA reaction behind the 3-2c deprotection base, water white transparency oily thing receives 44.1%, [α] 15 D:-15.8; IR (KBr, cm -1): 3421,2926,1749,1622,1548,1451,1362,1169; 1H NMR (CDCl 3, 300MHz): δ 8.06 (d, 2H, J=7.8Hz, Ar-H), 7.72 (m, 2H, Ar-H), 7.61 (m, 3H, Ar-H, N H), 7.44 (m, 1H, Ar-H), 7.33 (m, 1H, Ar-H), 7.29 (m, 1H, Ar-H), 5.24 (t, 1H, J=7.5Hz, SCH 2C H), 5.05-5.13 (m, 4H, 2 * CH 2CH=CCH 3, COOC H 2), 4.90 (m, 3H, NC H, C H 2O), 3.54 (d, 2H, J=7.8Hz, SC H 2), 1.98 (m, 8H, 2 * CHC H 2C H 2CH), 1.50-1.69 (m, 15H, 4 * CH=CC H 3, NCHC H 3); MS (ESI) m/z=722[M+1] +.
Embodiment 21
N-Boc-phenylalanine-2-{[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group } preparation of ethyl ester (3-4k)
With reference to the preparation method of 3-1g, make white solid, yield 58%, mp:108～109 ℃ by Boc-L-phenylalanine and 1k reaction.
N-{2-phenylpropionic acid-2-[[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group] ethyl ester } farnesyl thiosalicylic acid acid amides (II 10) preparation
With reference to II 1The preparation method, make water white transparency oily thing, yield 60%, [α] with FTA reaction behind the 3-4k deprotection base 26 D:-2.5; IR (KBr, cm -1): 3286,2923,1737,1642,1612,1552,1453,1355,1157; 1H NMR (CDCl 3, 300MHz): δ 8.03 (d, 2H, J=7.5Hz, Ar-H), 7.71 (m, 2H, Ar-H), 7.57 (m, 3H, Ar-H), 7.48 (m, 1H, Ar-H), 7.26-7.41 (m, 6H, Ar-H), 5.16-5.22 (m, 3H, 3 * CH 2C H=CCH 3), 4.52 (t, 2H, J=4.5Hz, COOC H 2), 4.27 (m, 3H, NC H, OC H 2), 3.89-3.96 (m, 4H, OCH 2C H 2OC H 2), 3.21-3.36 (m, 4H, SC H 2, CHC H 2), 2.01 (m, 8H, 2 * CHC H 2C H 2CH), 1.47-1.67 (m, 12H, 4 * CH=CCH 3); MS (ESI) m/z=818[M+1] +.
Embodiment 22
N-Boc-L-proline(Pro)-1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of propyl ester (3-3g)
With reference to the preparation method of 3-1g, make faint yellow oily thing, yield 58.7% by Boc-L-proline(Pro) and 1g reaction.
N-{2-Pyrrolidine formic acid-1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] propyl ester } the inferior acid amides (II of farnesyl thiosalicylic acid 11) preparation
With reference to II 1The preparation method, make faint yellow solid, yield 37.2%, [α] with FTA reaction behind the 3-3g deprotection base 25 D:-18.6; IR (KBr, cm -1): 3326,2927,1743,1626,1552,1449,1368,1169; 1H NMR (CDCl 3, 300MHz): δ 8.07 (d, 2H, J=7.5Hz, Ar-H), 7.71 (m, 1H, Ar-H), 7.61 (m, 2H, Ar-H), 7.34 (m, 2H, Ar-H), 7.22 (m, 2H, Ar-H), 5.22 (t, 1H, J=6.3Hz, SCH 2C H), 5.08 (t, 2H, J=5.1Hz, 2 * CH 2C H=CCH 3), 4.67 (m, 1H, NC H), 4.65-4.50 (m, 2H, NC H, OC H), 3.80 (m, 2H, OC H 2), 3.52 (d, 2H, J=7.2Hz, SC H 2), 3.30 (m, 2H, NC H 2), 2.29 (m, 2H, OCHC H 2), 1.98 (m, 8H, 2 * CHC H 2C H 2CH), 1.52-1.67 (m, 16H, NCHC H 2, 4 * CH=CC H 3, NCH 2C H 2), 1.24 (d, 3H, J=6.3Hz, CHC H 3); MS (ESI) m/z=752[M+1] +.
Embodiment 23
N-Boc-L-proline(Pro)-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)]-preparation of 2-alkynes-butyl ester (3-3c)
With reference to the preparation method of 3-1g, make faint yellow oily thing, yield 60.0% by Boc-L-proline(Pro) and 1c reaction.
N-{2-Pyrrolidine formic acid-4-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)]-2-alkynes-butyl ester } the inferior acid amides (II of farnesyl thiosalicylic acid 12) preparation
With reference to II 1The preparation method, make water white transparency oily thing, yield 46.1%, [α] with FTA reaction behind the 3-3c deprotection base 25 D:-30.3; IR (KBr, cm -1): 3439,2926,1752,1618,1548,1450,1362,1169; 1H NMR (CDCl 3, 300MHz): δ 8.07 (d, 2H, J=7.2Hz, Ar-H), 7.74 (m, 1H, Ar-H), 7.61 (m, 2H, Ar-H), 7.37 (m, 2H, Ar-H), 7.28 (m, 2H, Ar-H), 5.24 (t, 1H, J=7.5Hz, SCH 2C H), 5.08 (m, 4H, 2 * CH 2C H=CCH 3, COOC H 2), 4.82 (m, 2H, C H 2O), 4.71 (t, 1H, J=3.9Hz, NC H), 3.57 (d, 2H, J=7.5Hz, SC H 2), 3.30 (m, 2H, NC H 2), 2.29 (m, 2H, OCHC H 2), 1.98 (m, 10H, 2 * CHC H 2C H 2CH, NCHC H 2), 1.58-1.75 (m, 14H, 4 * CH=CC H 3, NCH 2C H 2); MS (ESI) m/z=748[M+1] +.
Embodiment 24
N-Boc-L-proline(Pro)-2-{[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group } preparation of ethyl ester (3-3k)
With reference to the preparation method of 3-1g, make colorless oil, yield 81.8% by Boc-L-proline(Pro) and 1k reaction.
N-{2-Pyrrolidine formic acid-2-[[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group] ethyl ester } the inferior acid amides (II of farnesyl thiosalicylic acid 13) preparation
With reference to II 1The preparation method, make water white transparency oily thing, yield 48.3%, [α] with FTA reaction behind the 3-3k deprotection base 25 D:-19.1; IR (KBr, cm -1): 3434,2917,1744,1628,1552,1448,1360,1170; 1H NMR (CDCl 3, 300MHz): δ 8.04 (d, 2H, J=8.1Hz, Ar-H), 7.73 (m, 2H, Ar-H), 7.61 (m, 2H, Ar-H), 7.23-7.39 (m, 3H, Ar-H), 5.27 (t, 1H, J=6.3Hz, SCH 2C H), 5.08 (t, 2H, J=5.1Hz, 2 * CH 2C H=CCH 3), 4.57 (t, 2H, J=4.5Hz, COOC H 2), 4.39 (t, 3H, J=4.5Hz, C H 2OCN), 4.11 (m, 1H, NC H), 3.93 (t, 2H, J=4.5Hz, COOCH 2C H 2O), 3.83 (t, 2H, J=4.5Hz, COOCH 2OC H 2), 3.55 (d, 2H, J=7.5Hz, SC H 2), 3.33 (m, 2H, NC H 2), 1.96-2.04 (m, 10H, NCHC H 2, 2 * CHC H 2C H 2CH), 1.52-1.67 (m, 14H, 4 * CH 3, NCH 2C H 2); MS (ESI) m/z=768[M+1] +.
Embodiment 25
N-Boc-glycine-2-{[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group } preparation of ethyl ester (3-1k)
Preparation method with reference to 3-1g makes white solid by 1k, yield 80%, mp:89～91 ℃.IR(KBr，cm -1)v：3359，2979，2941，1755，1681，1625，1562，1529，1456，1363，1164； 1H-NMR(300MHz，DMSO-d6)δ：1.37(s，9H，3CH 3)，3.63～3.71(m，4H，OCH 2，NCH 2)，3.79～3.82(m，2H，OCH 2)，4.18～4.21(m，2H，OCH 2)，4.50～4.53(m，2H，OCH 2)，7.19(brs，1H，NH)，7.72～7.77(m，2H，ArH)，7.88～7.93(m，1H，ArH)，8.01～8.03(m，2H，ArH)；ESI-MS(m/z)：487.7[M+H] +.
Glycine-2-{[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group } preparation of ethyl ester trifluoroacetate (4-1k)
Preparation method with reference to 4-1g is made by 3-1k, ESI-MS (m/z): 388.1[M+H] +.
N-{ acetate-2-[[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group] ethyl ester } farnesyl thiosalicylic acid acid amides (II 14) preparation
With reference to II 1The preparation method, make water white transparency oily thing 0.22g, yield 53%, IR (KBr, cm by FTA and 4-1k reaction -1): 3422,2927,1749,1628,1553,1449,1362,1168; 1H NMR (CDCl 3, 300MHz): δ 8.05 (d, 2H, J=8.1Hz, Ar-H), 7.73 (m, 2H, Ar-H), 7.62 (m, 2H, Ar-H), 7.39-7.42 (m, 4H, Ar-H), 5.27 (t, 1H, J=6.3Hz, SCH 2C H), 5.08 (t, 2H, J=5.4Hz, 2 * CH 2C H=CCH 3), 4.56 (t, 2H, J=4.5Hz, COOC H 2), 4.40 (t, 3H, J=4.5Hz, C H 2OCN), 4.31 (s, 1H, NC H 2), 3.93 (t, 2H, J=4.5Hz, COOCH 2C H 2O), 3.84 (t, 2H, J=4.5Hz, COOCH 2OC H 2), 3.54 (d, 2H, J=7.5Hz, SC H 2), 2.01 (m, 8H, 2 * CHC H 2C H 2CH), 1.47-1.67 (m, 12H, 4 * CH 3); MS (ESI) m/z=728[M+1] +.
Embodiment 26
N-Boc-{N '-2-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] propyl group }-preparation of L-alanimamides (3-3e)
With reference to the preparation method of 3-1g, make white solid, yield 50.2%, mp:127～131 ℃ by N-tert-butoxycarbonyl-l-alanine and 1e reaction.
N-{N '-[2-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] propyl group]-the 2-propionic acid amide } farnesyl thiosalicylic acid acid amides (II 15) preparation
With reference to II 1The preparation method, make water white transparency oily thing, yield 39.4%, IR (KBr, cm with FTA reaction behind the 3-3e deprotection base -1) v:3402,2907,1714,1624,1550,1452,1388; 1H NMR (CDCl 3, 300MHz): δ 8.03 (d, 2H, J=8.1Hz, Ar-H), 7.72 (m, 2H, Ar-H), 7.60 (m, 2H, Ar-H), 7.21-7.35 (m, 3H, Ar-H), 6.64 (m, 1H, CONH), 6.29 (d, 1H, J=9.0Hz, NH), 5.27 (t, 1H, J=6.3Hz, SCH 2C H), 5.08 (t, 2H, J=5.1Hz, 2 * CH 2C H=CCH 3), 4.56 (t, 2H, J=4.5Hz, COOC H 2), 4.31 (m, 2H, NC H 2), 3.73 (m, 2H, COOCH 2C H 2), 3.54 (d, 2H, J=7.5Hz, SC H 2), 2.01 (m, 8H, 2 * CHC H 2C H 2CH), 1.45-1.64 (m, 12H, 4 * CH 3), 1.50 (d, 2H, J=7.2Hz, NCHC H 3); ESI-MS (m/z): 711[M+H] +.
Embodiment 27
N-Boc-L-leucine-1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] preparation of propyl ester (3-5g)
With reference to the preparation method of 3-1g, make colorless oil, yield 90.1% by Boc-L-leucine and 1g reaction.
N-{2-isocaproic acid-1-methyl-3-[(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] propyl ester } farnesyl thiosalicylic acid acid amides (II 16) preparation
With reference to II 1The preparation method, make water white transparency oily thing, yield 51.2%, IR (KBr, cm with FTA reaction behind the 3-5g deprotection base -1) v:3413,2846,1717,1616,1551,1515,1454,1380,1169; 1H NMR (CDCl 3, 300MHz): δ 8.05 (d, 2H, J=8.1Hz, Ar-H), 7.70 (m, 1H, Ar-H), 7.58 (m, 2H, Ar-H), 7.40 (m, 2H, Ar-H), 7.29 (m, 2H, Ar-H), 5.25 (t, 1H, J=6.6Hz, SCH 2C H), 5.06 (m, 3H, 2 * CH 2C H=CCH 3, NC H), 5.13～5.21 (m, 1H, OCH), 4.45～4.50 (t, 2H, J=6.0Hz, OCH 2), 3.54 (d, 2H, J=7.5Hz, SC H 2), 2.20 (m, 2H, OCHC H 2), 1.91-2.05 (m, 10H, CHC H 2CH, 2 * CHC H 2C H 2CH), 1.56-1.68 (m, 12H, 4 * CH=CC H 3), 1.37-1.51 (m, 4H, OCHC H 3, CH 3C HCH 3), 0.80～1.08 (m, 6H, 2CH 3); .ESI-MS (m/z): 768[M+H] +.
Embodiment 28
N-Boc-Beta-alanine-2-{[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group } preparation of ethyl ester (3-6k)
With reference to the preparation method of 3-1g, make colorless oil, yield 29.9% by Boc-Beta-alanine and 1k reaction.
N-{ propionic acid-2-[[2-(4-benzenesulfonyl-5-oxygen-1,2, the oxygen of 5-oxadiazole-3-)] oxyethyl group] ethyl ester } farnesyl thiosalicylic acid acid amides (II 17) preparation
With reference to II 1The preparation method, make water white transparency oily thing, yield 35.7%, IR (KBr, cm-1) v:3415,2935,1731,1650,1550,1454,1388,1186 with FTA reaction behind the 3-6k deprotection base; 1H NMR (CDCl 3, 300MHz): δ 8.04 (d, 2H, J=8.1Hz, Ar-H), 7.72 (m, 2H, Ar-H), 7.61 (m, 2H, Ar-H), 7.39-7.41 (m, 4H, Ar-H), 6.22 (brs, 1H, NH), 5.25 (t, 1H, J=6.3Hz, SCH 2C H), 5.07 (t, 2H, J=5.4Hz, 2 * CH 2C H=CCH 3), 4.56 (t, 2H, J=4.5Hz, COOC H 2), 4.40 (t, 3H, J=4.5Hz, C H 2OCN), 4.30 (s, 1H, NC H 2), 3.93 (t, 2H, J=4.5Hz, COOCH 2C H 2O), 3.82 (t, 2H, J=4.5Hz, COOCH 2OC H 2), 3.54 (d, 2H, J=7.5Hz, SC H 2), 1.96-2.01 (m, 8H, 2 * CHC H 2C H 2CH), 1.47-1.66 (m, 12H, 4 * CH 3); ESI-MS (m/z): 742[M+H] +.

Claims (7)

1. farnesyl thio-salicylic acid derivative shown in general formula I, the II and medically acceptable salt thereof:
Figure FSA00000083319100011
In the general formula I: X representative-O-,-N-or-NH-; R representative-(CH 2) n-, n=2～6 ,-CH (CH 3) CH 2-,-CH (CH 3) (CH 2) 2-,-(CH 2) 2O (CH 2) 2-,-PhCH 2-,-(CH 2CH 2OH) CH 2CH 2-,-(CH 2) 2NH (CH 2) 2-,-(CH 2) 2NBoc (CH 2) 2-,-(CH 3) CH 2CH 2-,-(CH 2CH 2) 2NCH 2CH 2-,-(CH 2CH 2) 2CH (CH 2) n-, n=0～2 ,-(CH 2CH 2CH 2) CHCH 2-,-CH 2CH=CHCH 2-or-CH 2C ≡ CCH 2-;
Figure FSA00000083319100012
Among the general formula I I :-NH-A-CO-represents glycine, Beta-alanine, γ-An Jidingsuan, L-or D-type L-Ala, L-or D-type Xie Ansuan, L-or D-type leucine, L-or D-type Isoleucine, L-or D-type methionine(Met), L-or D-type halfcystine, L-or D-type phenylalanine, L-or D-type tyrosine, L-or D-type tryptophane, L-or D-type arginine, L-or D-type proline(Pro), L-or D-type histidine residues; X representative-O-,-N-or-NH-; R representative-(CH 2) n-, n=2～6 ,-CH (CH 3) CH 2-,-CH (CH 3) (CH 2) 2-,-(CH 2) 2O (CH 2) 2-,-PhCH 2-,-(CH 2CH 2OH) CH 2CH 2-,-(CH 2) 2NH (CH 2) 2-,-(CH 2) 2NBoc (CH 2) 2-,-(CH 3) CH 2CH 2-,-(CH 2CH 2) 2NCH 2CH 2-,-(CH 2CH 2) 2CH (CH 2) n-, n=0～2 ,-(CH 2CH 2CH 2) CHCH 2-,-CH 2CH=CHCH 2-or-CH 2C ≡ CCH 2-.
2. farnesyl thio-salicylic acid derivative according to claim 1 and medically acceptable salt thereof is characterized in that: X representative-O-in the general formula I ,-N-or-NH-; R representative-(CH 2) n-, n=2～6 ,-CH (CH 3) (CH 2) 2-,-(CH 2) 2O (CH 2) 2-,-(CH 2CH 2OH) CH 2CH 2-,-(CH 2) 2NH (CH 2) 2-,-(CH 2) 2NBoc (CH 2) 2-,-(CH 3) CH 2CH 2-,-(CH 2CH 2) 2CH-,-(CH 2CH 2) 2NCH 2CH 2-,-(CH 2CH 2CH 2) CHCH 2-or-CH 2C ≡ CCH 2-.
3. farnesyl thiosalicylic acid (FTA) derivative according to claim 1 and medically acceptable salt thereof, it is characterized in that, among the general formula I I-NH-A-CO-represents glycine, Beta-alanine, L-type L-Ala, L-type phenylalanine, L-type proline(Pro) or L-type leucine residue; X representative-O-,-N-or-NH-; R representative-(CH 2) n-, n=2～6 ,-CH (CH 3) (CH 2) 2-,-(CH 2) 2O (CH 2) 2-or-CH 2C ≡ CCH 2-.
4. the preparation method of the described farnesyl thio-salicylic acid derivative of claim 1 is characterized in that:
Farnesyl thiosalicylic acid (FTA) derivative shown in the general formula I prepares by following manner: 2-oxygen-3; 4-two benzenesulfonyls-1; 2; the 5-oxadiazole generates furazan oxynitride (1) with hydrocarbon based diol or the reaction of alkyl hydramine under the sodium hydroxide effect; farnesyl thiosalicylic acid (FTA) is at N; N '-dicyclohexylcarbodiimide (DCC) and DMAP effect are descended and furazan oxynitride (1) reaction makes compound of Formula I, and its synthetic route is as follows:
Figure FSA00000083319100021
Figure FSA00000083319100022
Wherein, the definition of X and R according to claim 1.
Farnesyl thiosalicylic acid (FTA) derivative shown in the general formula I I prepares by following manner: under DCC and DMAP effect; furazan oxynitride (1) generates intermediate (3) with amino acid (2) reaction of Boc protection; take off Boc through trifluoroacetic acid (TFA) and obtain compound (4); under 1-ethyl-(3-dimethylaminopropyl) carbodiimide (EDC) and DMAP effect; make with farnesyl thiosalicylic acid (FTA) reaction, its synthetic route is as follows:
Figure FSA00000083319100031
Wherein ,-definition of NH-A-CO-, X and R is according to claim 1.
5. a pharmaceutical composition is gone up the described general formula I of claim 1, II compound and pharmaceutically acceptable carrier or the auxiliary material of effective dose and is formed by treatment.
6. the described general formula I of claim 1, the II compound purposes in the preparation antitumor drug.
7. the purposes of claim 6, wherein tumor disease is liver cancer, kidney, lung cancer, mammary cancer, the cancer of the brain, cancer of the stomach, colorectal carcinoma, ovarian cancer, uterus carcinoma, bladder cancer, prostate cancer, carcinoma of the pancreas, oral carcinoma, laryngocarcinoma, the esophageal carcinoma, skin carcinoma or leukemia.
CN2010101460292A 2010-04-14 2010-04-14 Nitric oxide donor-type farnesyl thiosalicylic acid derivative, and preparation method and medical application thereof Expired - Fee Related CN101812059B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010101460292A CN101812059B (en) 2010-04-14 2010-04-14 Nitric oxide donor-type farnesyl thiosalicylic acid derivative, and preparation method and medical application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010101460292A CN101812059B (en) 2010-04-14 2010-04-14 Nitric oxide donor-type farnesyl thiosalicylic acid derivative, and preparation method and medical application thereof

Publications (2)

Publication Number Publication Date
CN101812059A true CN101812059A (en) 2010-08-25
CN101812059B CN101812059B (en) 2012-05-02

Family

ID=42619438

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010101460292A Expired - Fee Related CN101812059B (en) 2010-04-14 2010-04-14 Nitric oxide donor-type farnesyl thiosalicylic acid derivative, and preparation method and medical application thereof

Country Status (1)

Country Link
CN (1) CN101812059B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702052A (en) * 2012-06-18 2012-10-03 南通大学 Novel diamine-containing farnesyl thiosalicylic acid derivative and preparation method and medicinal application thereof
CN103864720A (en) * 2014-01-23 2014-06-18 南通大学 Phenyl acrylic acid farnesyl thiosalicylic acid (FTA) derivative as well as preparation method and application
CN104292139A (en) * 2014-08-25 2015-01-21 南通大学 Farnesylated thioether-substituted chalcone derivative, preparation method and purpose thereof
CN104292140A (en) * 2014-08-25 2015-01-21 南通大学 Farnesyl thiosalicylic acid analogue containing chalcone framework, preparation method and purpose thereof
CN104292167A (en) * 2014-09-18 2015-01-21 成都大学 Nitric oxide donor derivatives of bendamustine hydrochloride and preparation method of nitric oxide donor derivatives
CN104693257A (en) * 2015-02-03 2015-06-10 南通大学 Benzenesulfonyl furazan modified gemcitabine derivative and preparation method and use thereof
CN106946868A (en) * 2016-12-18 2017-07-14 何黎琴 Nitric oxide donator type coumarin derivative, its preparation method and medical usage
CN108658962A (en) * 2017-03-30 2018-10-16 复旦大学 3- substituted cumarins Furazan Derivatives and its purposes in preparing anti-multidrug resistance of tumor drug
CN111072682A (en) * 2019-11-07 2020-04-28 沈阳药科大学 Chelidonine furazan nitric oxide donor derivative and preparation method and application thereof
CN112047953A (en) * 2019-06-06 2020-12-08 天津尚德药缘科技股份有限公司 Parthenolide-benzenesulfonyl furazan derivative and salt thereof, preparation method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101402667A (en) * 2008-09-11 2009-04-08 中国药科大学 Glycosylation modified nitric oxide donor type oleaolic acid compounds, preparation and uses thereof
CN101530411A (en) * 2009-04-14 2009-09-16 中国药科大学 Application for taking NO donor-type compounds as P-glycoprotein inhibitors and tumor multi-drug resistance reversal agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101402667A (en) * 2008-09-11 2009-04-08 中国药科大学 Glycosylation modified nitric oxide donor type oleaolic acid compounds, preparation and uses thereof
CN101530411A (en) * 2009-04-14 2009-09-16 中国药科大学 Application for taking NO donor-type compounds as P-glycoprotein inhibitors and tumor multi-drug resistance reversal agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《Bioorganic & Medicinal Chemistry》 20100403 Yong Ling, et al Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents 3448-3456 1-7 第18卷, 2 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702052B (en) * 2012-06-18 2013-12-11 南通大学 Novel diamine-containing farnesyl thiosalicylic acid derivative and preparation method and medicinal application thereof
CN102702052A (en) * 2012-06-18 2012-10-03 南通大学 Novel diamine-containing farnesyl thiosalicylic acid derivative and preparation method and medicinal application thereof
CN103864720B (en) * 2014-01-23 2016-01-20 南通大学 Derived from phenyl acrylic acid farnesyl thio-salicylic acid derivative and preparation method and purposes
CN103864720A (en) * 2014-01-23 2014-06-18 南通大学 Phenyl acrylic acid farnesyl thiosalicylic acid (FTA) derivative as well as preparation method and application
CN104292139B (en) * 2014-08-25 2016-04-13 南通大学 The chalcone derivative that farnesyl thioether replaces and preparation method and purposes
CN104292140A (en) * 2014-08-25 2015-01-21 南通大学 Farnesyl thiosalicylic acid analogue containing chalcone framework, preparation method and purpose thereof
CN104292139A (en) * 2014-08-25 2015-01-21 南通大学 Farnesylated thioether-substituted chalcone derivative, preparation method and purpose thereof
CN104292167A (en) * 2014-09-18 2015-01-21 成都大学 Nitric oxide donor derivatives of bendamustine hydrochloride and preparation method of nitric oxide donor derivatives
CN104693257A (en) * 2015-02-03 2015-06-10 南通大学 Benzenesulfonyl furazan modified gemcitabine derivative and preparation method and use thereof
CN106946868A (en) * 2016-12-18 2017-07-14 何黎琴 Nitric oxide donator type coumarin derivative, its preparation method and medical usage
CN106946868B (en) * 2016-12-18 2019-12-03 何黎琴 Nitric oxide donator type coumarin derivative, preparation method and medical usage
CN108658962A (en) * 2017-03-30 2018-10-16 复旦大学 3- substituted cumarins Furazan Derivatives and its purposes in preparing anti-multidrug resistance of tumor drug
CN108658962B (en) * 2017-03-30 2021-10-01 复旦大学 3-substituted coumarin furazan derivative and application thereof in preparation of multidrug-resistant tumor drugs
CN112047953A (en) * 2019-06-06 2020-12-08 天津尚德药缘科技股份有限公司 Parthenolide-benzenesulfonyl furazan derivative and salt thereof, preparation method and application
CN112047953B (en) * 2019-06-06 2023-12-29 天津尚德药缘科技股份有限公司 Parthenolide-benzenesulfonyl furazan derivative and salt thereof, preparation method and application thereof
CN111072682A (en) * 2019-11-07 2020-04-28 沈阳药科大学 Chelidonine furazan nitric oxide donor derivative and preparation method and application thereof

Also Published As

Publication number Publication date
CN101812059B (en) 2012-05-02

Similar Documents

Publication Publication Date Title
CN101812059B (en) Nitric oxide donor-type farnesyl thiosalicylic acid derivative, and preparation method and medical application thereof
RO119413B1 (en) Isoster derivatives of aspartate-protease substrate, salts thereof, pharmaceutical compositions and use
TW200914460A (en) Proteasome inhibitors
CN109071423A (en) Indoles amine -2,3- dioxygenase (IDO) inhibitor
KR20140038972A (en) Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
CN102471248A (en) Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid
DK2615092T3 (en) Heterocyclic AMINOBERBAMIN DERIVATIVES, PREPARATION METHOD AND USE THEREOF
JP2021526159A (en) Synthesis and use of peptide boronic acid esters compounds
CN108440583A (en) A kind of new boronic acid derivatives and its pharmaceutical composition
AU2017361856A1 (en) Use of sanglifehrin macrocyclic analogues as anticancer compounds
CN107207525B (en) The triptolide amino acid derivativges of C14- hydroxy esterifications, and its preparation method and application
EP3680232A1 (en) NOVEL ANTHRANILIC ACID-BASED COMPOUND, AND Pin1 INHIBITOR, THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES AND THERAPEUTIC AGENT FOR CANCER THAT USE THE SAME
CN112010839A (en) Crystalline forms of a targeted silk/threonine kinase inhibitor
CN104230952A (en) Compound containing pyrimidine skeleton, and preparation method and use of compound
EP2759547B1 (en) Platinum compound having amino- or alkylamino-containing succinic acid derivatives as leaving group, preparation method therefor, and use thereof
AU2015240775B2 (en) Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
CN104592091A (en) Compound containing Indole acetic acid core structure and application of compound
US11712435B2 (en) Mebendazole prodrugs with enhanced solubility and oral bioavailability
EP3680233A1 (en) NOVEL AMIDE COMPOUND, AND Pin1 INHIBITOR, THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES AND THERAPEUTIC AGENT FOR CANCER THAT USE THE SAME
US9518038B2 (en) Condensation product of theanine derivative and carboxylic acid coumarin derivative, its intermediate, preparation method and use thereof
CN110522923A (en) The matrix material of fructose and the co-modified dual-target triple negative breast cancer of RGD peptide
TW201922690A (en) Inhibitors of cyclic-AMP response element-binding protein
CN111393368B (en) Indenopyrazole hydrochloride derivative and preparation method and application thereof
CN105960399B (en) Enzyme inhibitor epoxy ketone compound
CN103864720B (en) Derived from phenyl acrylic acid farnesyl thio-salicylic acid derivative and preparation method and purposes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120502

Termination date: 20130414